OPKO Health Inc
Slēgts
SektorsVeselības aprūpe
1.54 -1.28
Pārskats
Akcijas cenas izmaiņa
24h
Min
1.55
Max
1.56
Ienākumi | 46M -8.4M |
|---|---|
Pārdošana | 39M 164M |
EPS | -0.01 |
Peļņas marža | -5.145 |
Darbinieki | 2,275 |
EBITDA | 40M 12M |
Nākamie ieņēmumi | 2026. g. 28. okt. |
|---|
Tirgus kapitalizācija | 318M 1.2B |
|---|---|
Iepriekšējā atvēršanas cena | 2.82 |
Iepriekšējā slēgšanas cena | 1.54 |
Ziņu noskaņojums
By Acuity
31%
69%
60 / 339 Rangs Healthcare
OPKO Health Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
OPKO Health Inc Prognoze
Noskaņojums
By Acuity
60 / 339 Rangs Veselības aprūpe
Ziņu noskaņojums
Liecība "Buļļu" tendencei
Volatilitāte
Zem vidējā
Ziņu apjoms (RCV)
Zem vidējā
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$
Par OPKO Health Inc
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.